Investment Thesis — McKesson Corporation
The market is extrapolating McKesson's recent outperformance as a function of sector momentum and defensive healthcare flows, missing the structural shift in drug distribution power and the company's growing leverage over payors and manufacturers. This pricing power is masked by razor-thin margins and a misunderstood business model, leading to persistent mispricing of its earnings durability.
Catalysts
- Reimbursement rate changes or regulatory action on drug pricing
- Unexpected margin compression from supply chain normalization
- Major contract wins or renewals with large healthcare systems
Risk Factors
- Regulatory intervention targeting distributor margins
- Reversal of recent margin expansion due to competitive pressures
- Sector rotation out of defensive healthcare names
Key Debates
Fwd Revenue Growth Exceeds 15% by H2 2024
MCK's 24x Fwd P/E Compresses to 20x by Q1 2025
Operating Margins Expand 50bps by Q3 2024